Tolerability and comparative effectiveness of TNF, IL-17 and IL-23(p19) inhibitors in psoriatic arthritis: a target trial emulation study

被引:4
|
作者
Stisen, Zara R. [1 ]
Nielsen, Sabrina M. [1 ,2 ]
Skougaard, Marie [1 ,3 ]
Mogensen, Mette [4 ,5 ]
Jorgensen, Tanja Schjodt [1 ]
Dreyer, Lene [6 ]
de Wit, Maarten [7 ]
Christensen, Robin [1 ,2 ]
Kristensen, Lars Erik [1 ]
机构
[1] Univ Copenhagen, Bispebjerg & Frederiksberg Hosp, Parker Inst, Nordre Fasanvej 57, DK-2000 Copenhagen, Denmark
[2] Univ Southern Denmark, Odense Univ Hosp, Dept Clin Res, Res Unit Rheumatol, Odense, Denmark
[3] Aarhus Univ Hosp, Dept Clin Immunol, Skejby, Denmark
[4] Bispebjerg & Frederiksberg Hosp, Dept Dermatol, Copenhagen, Denmark
[5] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[6] Aalborg Univ, Aalborg Univ Hosp, Ctr Rheumat Res Aalborg CERRA, Dept Rheumatol, Aalborg, Denmark
[7] Stichting Tools Patient Res Partner, Amsterdam, Netherlands
关键词
psoriatic arthritis; biological therapy; drug survival;
D O I
10.1093/rheumatology/kead488
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To compare the tolerability and effectiveness of two different classes of biological DMARDs [IL-17 and IL-23(p19) inhibitors, IL-17i and IL-23(p19)i] relative to TNF inhibitors (TNFi) regarding the drug survival rates and treatment outcomes in patients with PsA.Methods We emulated a target trial on comparative effectiveness using observational data from a prospective cohort study based on the Parker Institute's PsA cohort (the PIPA cohort). All patients underwent interview and a clinical examination programme at baseline and at follow-up visits at 4 and 12 months. The primary endpoint, drug survival, was assessed up to 12 months from baseline. We estimated hazard ratios from proportional hazards model and used propensity score adjustment in an attempt to deconfound and emulate a random treatment assignment.Results We included a total of 109 patients in the intention-to-monitor population at baseline initiating either TNFi (75 patients), IL-17i (26 patients) or IL-23(19)i (8 patients). Hazard ratios in the propensity adjusted model comparing IL-17i and IL-23(p19)i with TNFi were 1.36 (95% CI 0.59-3.14) and 0.56 (95% CI 0.10-3.24), respectively. TNFi and IL-17i had comparable effects regarding response rates and changes in clinical outcomes after 12 months, whereas IL-23(p19)i tended to perform better overall.Conclusion No decisive differences between drugs were observed at group level regarding drug survival and clinical outcomes after 12 months. TNFi, IL-17i and IL-23(p19)i may all be considered equally effective in the treatment of patients with PsA, advocating for investigating more in personalized treatment strategies.
引用
收藏
页码:1543 / 1551
页数:9
相关论文
共 50 条
  • [41] Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
    Andrew Blauvelt
    Andrea Chiricozzi
    Benjamin D. Ehst
    Mark G. Lebwohl
    Advances in Therapy, 2023, 40 : 3410 - 3433
  • [42] Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics?
    Aguero, Rosario
    Woodbury, Michael J.
    Lee, Kathryn
    Johnsson, Hanna J.
    Merola, Joseph F.
    Armstrong, April W.
    JOURNAL OF RHEUMATOLOGY, 2023, 50 (11) : 11 - 13
  • [43] Treatment with IL-17 Inhibitors Is Associated with Reduced eGFR in Patients with Psoriasis or Psoriatic Arthritis: A Retrospective Cohort Study
    Tsai, Peihsuan R.
    Gilroy, Daniel X.
    Le, Thu H.
    Drury, Erika
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 733 - 733
  • [44] Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study
    Perrotta, F. M.
    Delle Sedie, A.
    Scriffignano, S.
    Volpe, P.
    Cordisco, E.
    Milano, N.
    Gabini, M.
    Lubrano, E.
    REUMATISMO, 2020, 72 (01) : 52 - 59
  • [45] Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis
    Wu, Shuwei
    Xu, Yuanyuan
    Yang, Lihua
    Guo, Linghong
    Jiang, Xian
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [46] Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study
    Huang, Dawei
    Yu, Yingyuan
    Lu, Jiajing
    Tan, Fei
    Shi, Yuling
    FRONTIERS IN MEDICINE, 2023, 10
  • [47] TLR2 deficiency by compromising p19 (IL-23) expression limits Th 17 cell responses to Mycobacterium tuberculosis
    Teixeira-Coelho, Maria
    Cruz, Andrea
    Carmona, Jenny
    Sousa, Carole
    Ramos-Pereira, Daniela
    Saraiva, Ana Laura
    Veldhoen, Marc
    Pedrosa, Jorge
    Castro, Antonio G.
    Saraiva, Margarida
    INTERNATIONAL IMMUNOLOGY, 2011, 23 (02) : 89 - 96
  • [48] Authors’ reply to Borg and Thoning: “Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study”
    Tiago Torres
    Andrea Chiricozzi
    Luis Puig
    American Journal of Clinical Dermatology, 2021, 22 : 903 - 904
  • [49] Authors' reply to Borg and Thoning: "Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study"
    Torres, Tiago
    Chiricozzi, Andrea
    Puig, Luis
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (06) : 903 - 904
  • [50] Normalization of the microbiome in psoriatic skin after treatment with fumaric acid esters (FAE), TNF, IL-17 or PDE4-inhibitors but not IL-12/23 blockade
    Magnolo, N.
    Tsianakas, A.
    Mykicki, N.
    Luger, T.
    Loser, K.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S206 - S206